Bisaryl compound and medicament for cancer treatment comprising the same
US6608061B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Feb 14, 2000 |
| Grant date | Aug 19, 2003 |
| Priority date | — |
| Expiry date | Feb 14, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H15/18
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof:Ar1—S—R1—S—Ar2 wherein R1 represents a nonmetal bridging group; Ar1 and Ar2 independently represent a group selected from the group consisting of an aryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group and said aryl group may have one to three substituents other than hydroxyl group on its ring; and a heteroaryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group, and said heteroaryl group may have one to three substituents other than hydroxyl group on its ring.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.